Vaccine Irony: COVID Complicates Review, Uptake Of New RSV Vaccines
Executive Summary
COVID vaccines saved the world and then became a liability. US FDA vaccine advisors cited COVID experience as they urge agency to slow down on approval of new RSV vaccines, due to worries of declining public vaccine confidence and coadministration complications.
You may also be interested in...
Quick And Flexible Vaccine Approval Must Include Postmarket Simplicity, US FDA’s Kaslow Says
After making the COVID-19 vaccines available, multiple presentations based on age and vaccination status created confusion that likely hindered uptake, said OVRR Director David Kaslow.
US FDA Chief Scientist Thinks Increased Data Literacy Can Counter Misinformation
Chief Scientist Namandjé Bumpus wants FDA to do more to ensure the accessibility of scientific information, arguing empowering people to understand data themselves may help the US counter misinformation.
COVID Vaccines: XBB Strain Easy Call, But Disagreements Abound Between FDA, Advisors On Logistics
It took little convincing for FDA advisors to support changing COVID-19 vaccines to monovalent XBB formulations, but the committee still isn’t sold on the agency’s annual influenza-like campaign strategy for COVID vaccines and raised several harder calls that FDA and CDC will need to make including when to cut off bivalent shots use and who should get XBB.